Cryoport, Inc. (NASDAQ:CYRX – Get Free Report) was the recipient of a significant decline in short interest during the month of July. As of July 31st, there was short interest totalling 3,360,000 shares, a decline of 6.7% from the July 15th total of 3,600,000 shares. Approximately 7.1% of the shares of the stock are sold short. Based on an average trading volume of 843,000 shares, the days-to-cover ratio is currently 4.0 days.
Cryoport Trading Down 2.3 %
NASDAQ CYRX opened at $9.17 on Wednesday. The company has a debt-to-equity ratio of 0.86, a quick ratio of 10.22 and a current ratio of 10.73. The firm has a market cap of $451.69 million, a price-to-earnings ratio of -3.71 and a beta of 1.59. The firm has a 50 day simple moving average of $8.22 and a 200-day simple moving average of $12.84. Cryoport has a one year low of $5.32 and a one year high of $20.10.
Cryoport (NASDAQ:CYRX – Get Free Report) last released its earnings results on Tuesday, August 6th. The company reported ($1.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($1.25). The business had revenue of $57.60 million for the quarter, compared to analyst estimates of $57.65 million. Cryoport had a negative return on equity of 15.19% and a negative net margin of 50.17%. Cryoport’s quarterly revenue was up 1.0% compared to the same quarter last year. During the same quarter last year, the company earned ($0.42) earnings per share. Equities research analysts anticipate that Cryoport will post -1.39 EPS for the current fiscal year.
Analyst Ratings Changes
Get Our Latest Research Report on CYRX
Insider Buying and Selling
In other Cryoport news, Director Ramkumar Mandalam sold 4,167 shares of the firm’s stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $8.04, for a total value of $33,502.68. Following the transaction, the director now directly owns 56,032 shares of the company’s stock, valued at approximately $450,497.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last three months, insiders have sold 6,167 shares of company stock worth $50,903. 10.10% of the stock is owned by insiders.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Comerica Bank increased its holdings in Cryoport by 73.0% during the 1st quarter. Comerica Bank now owns 3,481 shares of the company’s stock worth $62,000 after purchasing an additional 1,469 shares during the period. Natixis Investment Managers International grew its position in shares of Cryoport by 61.5% during the fourth quarter. Natixis Investment Managers International now owns 4,536 shares of the company’s stock worth $70,000 after buying an additional 1,727 shares in the last quarter. Quest Partners LLC grew its position in shares of Cryoport by 1,083,000.0% during the second quarter. Quest Partners LLC now owns 10,831 shares of the company’s stock worth $75,000 after buying an additional 10,830 shares in the last quarter. Hsbc Holdings PLC purchased a new stake in shares of Cryoport during the second quarter worth approximately $92,000. Finally, Lazard Asset Management LLC raised its holdings in Cryoport by 294.3% in the first quarter. Lazard Asset Management LLC now owns 5,378 shares of the company’s stock valued at $95,000 after acquiring an additional 4,014 shares in the last quarter. 92.90% of the stock is currently owned by hedge funds and other institutional investors.
Cryoport Company Profile
Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.
Featured Stories
- Five stocks we like better than Cryoport
- What Are Some of the Best Large-Cap Stocks to Buy?
- Columbia Sportswear: A Turnaround Story That’s Gaining Ground
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Lowe’s Stock: Hold Now, Buy it When it Dips
- What is an Earnings Surprise?
- ZIM Shipping Stock Soars as the Industry Shows a Bottoming Trend
Receive News & Ratings for Cryoport Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryoport and related companies with MarketBeat.com's FREE daily email newsletter.